PharmaLogic buys Lantheus's radiopharma CDMO plant to go transatlantic
- PharmaLogic agreed to buy Lantheus's radiopharmaceutical CDMO business and its Springfield, New Jersey plant; the price was not disclosed.
- The site has seven commercial-scale suites built for beta and alpha emitters. Staff will move to PharmaLogic's Norwegian unit Agilera, which will make Lu-177 dotatate for Lantheus.
- Lantheus is selling about 19 months after paying $250M upfront for Evergreen Theragnostics, and while it merges with Curium in an $8B deal due to close in 1H 2027.
💡 Points Based on public reports
Lantheus is shedding contract manufacturing to concentrate on its own products ahead of the Curium merger, a sign that CDMO work was not part of the combined company's core. For PharmaLogic, alpha-capable capacity in the US next to Agilera in Europe is a real selling point as AstraZeneca, BMS and Lilly push radioligands toward the clinic. Watch the undisclosed price against the $250M Evergreen cost, and whether anchor customers sign on.
📰 Source · BioSpace ↗ PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO